Michael Bookman, MD, of the University of Arizona Cancer Center will join Arizona Oncology, a practice in The US Oncology Network, and serve as Medical Director of the US Oncology Research Gynecology Research Program. In his new role, effective October 6, 2014, Dr. Bookman will use his extensive medical experience to bring more high-priority gynecologic clinical trials to US Oncology Research while managing the gynecologic oncology research portfolio and patient accrual at a national level.
Cutting-Edge Clinical Trials
“Dr. Bookman’s recruitment is an important next step as we strive to prevail over [ovarian and other gynecologic cancers],” said Michael Seiden, MD, Chief Medical Officer, The US Oncology Network. “Offering patients access to cutting-edge clinical trials in a community setting is a critical part of advancing the quality and science of cancer care. I’m confident Dr. Bookman will succeed in helping us to build a world-class gynecologic research program that achieves these goals.”
“Our clinical research environment is evolving rapidly, with an emphasis on industry-sponsored trials of molecular targeted agents, often in selected patient populations with predictive biomarkers, using smaller randomized pilots to select and validate promising regimens for definitive phase III trials,” said Dr. Bookman. “US Oncology Research is uniquely positioned to stay ahead of this trend and offer important trials to patients with a variety of gynecologic cancers, including rare diseases and uncommon molecular subtypes. I look forward to collaborating with our local teams.”
Dr. Bookman has more than 25 years of clinical trial experience, encompassing the intramural National Cancer Institute (NCI) program, Gynecologic Oncology Group (GOG), National Comprehensive Cancer Network, and positions at two NCI-designated comprehensive cancer centers. His extensive experience includes the multidisciplinary management of gynecologic oncology care, medical informatics, outcomes database development, budget and contract development for clinical research, and regulatory compliance. He continues to serve as Chair of the Ovarian Committee for GOG, which has been integrated with NRG Oncology under the NCI National Clinical Trials Network. He also serves as Director of Educational Resources for the International Gynecologic Cancer Society (IGCS), with a commitment to support meaningful outreach within the developing world. ■